MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Fulgent Genetics Cash Conversion Cycle 2011-2026 | FLGT
Annual Cash Conversion Cycle Fulgent Genetics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.4 | 27.6 | 24.9 | 19.6 | 25.4 | 47 | 72.6 | 4 | -40.8 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 72.6 | -40.8 | 24.7 |
Quarterly Cash Conversion Cycle Fulgent Genetics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.8 | 47.2 | 50.2 | - | 32.2 | 29.3 | 35.4 | - | 8.29 | 11.5 | 22.9 | - | 33.9 | 40.3 | 16.7 | 13.8 | 12.4 | 67.5 | 23.8 | 10.2 | 72.9 | 659 | 805 | 31.6 | 20.7 | 31.1 | 61.7 | 52.4 | 50.6 | 53.4 | 41.6 | 10.5 | -2.89 | -22.7 | -47 | -67 | -37.9 | -78 | -21.4 | 56.1 | 17.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 805 | -78 | 57.6 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
172 | $ 2.13 | - | $ 4.89 M |  USA |
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
97.3 | $ 75.5 | -0.31 % | $ 5.1 B | USA |
 |
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-38.7 | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
299 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 455.28 | -0.36 % | $ 13.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | USA |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 229.6 | -0.87 % | $ 25.3 B |  Schweiz |
 |
Charles River Laboratories International
CRL
|
65 | $ 156.54 | -0.92 % | $ 7.76 B | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 165.42 | -0.95 % | $ 28.4 B | USA |
 |
Myriad Genetics
MYGN
|
49.3 | $ 4.6 | -1.29 % | $ 426 M | USA |
 |
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
299 | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
166 | $ 1.25 | -14.38 % | $ 6.81 M | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 17.47 | -0.26 % | $ 391 M | USA |
 |
Interpace Biosciences
IDXG
|
44.9 | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
103 | $ 569.86 | -1.5 % | $ 45.8 B | USA |
 |
Illumina
ILMN
|
142 | $ 122.99 | -0.65 % | $ 19.6 B | USA |
 |
ICON Public Limited Company
ICLR
|
62 | $ 100.22 | -0.13 % | $ 8.27 B |  Irlanda |
 |
Guardant Health
GH
|
79.6 | $ 84.35 | -0.65 % | $ 10.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B |  Niderland |
 |
Pacific Biosciences of California
PACB
|
185 | $ 1.38 | -1.08 % | $ 414 M | USA |
 |
Precipio
PRPO
|
-3.19 | $ 26.93 | - | $ 35 M | USA |
 |
Personalis
PSNL
|
-11.5 | $ 7.71 | 1.37 % | $ 457 M | USA |
 |
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
40.3 | $ 263.52 | -0.36 % | $ 21.9 B | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K |  Israel |
 |
RadNet
RDNT
|
34.5 | $ 60.39 | -2.19 % | $ 4.54 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-1.24 K | $ 3.41 | -2.16 % | $ 1.83 M | USA |
 |
NeoGenomics
NEO
|
82.4 | $ 7.91 | -2.35 % | $ 1.01 B | USA |
 |
Agilent Technologies
A
|
111 | $ 111.72 | -0.27 % | $ 34 B | USA |
 |
Natera
NTRA
|
81.5 | $ 194.13 | -2.98 % | $ 19.1 B | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 17.24 | -1.82 % | $ 919 M | USA |
 |
OPKO Health
OPK
|
242 | $ 1.14 | -0.88 % | $ 791 M | USA |
 |
Senseonics Holdings
SENS
|
36.1 | $ 6.58 | -0.68 % | $ 275 M | USA |
 |
Castle Biosciences
CSTL
|
45.9 | $ 25.84 | 0.35 % | $ 718 M | USA |
 |
Sotera Health Company
SHC
|
33.5 | $ 13.77 | -0.79 % | $ 3.91 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
39.5 | $ 194.57 | -0.54 % | $ 21.6 B | USA |
 |
DarioHealth Corp.
DRIO
|
115 | $ 7.37 | -1.73 % | $ 29.4 M | Israel |